Probable Factors Associated with Response to Mesenchymal Stem Cell Therapy in Stroke Patients: A Post Hoc Analysis of the STARTING-2 Trial

The aim of this study was to identify factors associated with improved motor function of the lower extremities in response to mesenchymal stem cell (MSC) therapy in patients with ischemic stroke. This study was a post hoc analysis of data from a prospective, open-label, randomized controlled trial o...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Won Hyuk Chang, Jungsoo Lee, Jong-Won Chung, Yun-Hee Kim, Oh Young Bang, The STARTING-2 Collaborators
Formato:	article
Lenguaje:	EN
Publicado:	MDPI AG 2021
Materias:	mesenchymal stem cells stroke motor recovery post hoc analysis motor impairment Medicine R
Acceso en línea:	https://doaj.org/article/a80a79b6f65f4a5f9024672142dad666
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:a80a79b6f65f4a5f9024672142dad666
record_format	dspace
spelling	oai:doaj.org-article:a80a79b6f65f4a5f9024672142dad6662021-11-25T18:07:29ZProbable Factors Associated with Response to Mesenchymal Stem Cell Therapy in Stroke Patients: A Post Hoc Analysis of the STARTING-2 Trial10.3390/jpm111111372075-4426https://doaj.org/article/a80a79b6f65f4a5f9024672142dad6662021-11-01T00:00:00Zhttps://www.mdpi.com/2075-4426/11/11/1137https://doaj.org/toc/2075-4426The aim of this study was to identify factors associated with improved motor function of the lower extremities in response to mesenchymal stem cell (MSC) therapy in patients with ischemic stroke. This study was a post hoc analysis of data from a prospective, open-label, randomized controlled trial of MSC therapy for patients with ischemic stroke patients associated with severe middle cerebral artery territory (STARTING-2 trial). Lower limb motor function was scored based on the lower limb of Fugl–Meyer assessment (FMA-LL) score before MSC therapy and at 3 months after stroke. All FMA-LL changes greater than or equal to six points were considered clinically significant. Univariate and multivariate binary logistic regression models were used to determine possible predictors of clinically significant lower limb motor response to MSC therapy. Twelve (33%) of the thirty-six patients receiving MSC therapy reached a minimal clinically important difference (MCID) of FMA-LL. The two independent factors with the greatest impact on response to MSC therapy for achieving an MCID in FMA-LL score were: (1) the time from stroke onset to MSC therapy, and (2) age (<i>p</i> < 0.05). In addition, obese stroke patients responded better to MSC therapy than stroke patients with normal weight. In conclusion, this post hoc analysis might suggest the need for recruiting stroke patients at younger and early after stroke onset in future clinical trials of MSC therapy for stroke.Won Hyuk ChangJungsoo LeeJong-Won ChungYun-Hee KimOh Young BangThe STARTING-2 CollaboratorsMDPI AGarticlemesenchymal stem cellsstrokemotor recoverypost hoc analysismotor impairmentMedicineRENJournal of Personalized Medicine, Vol 11, Iss 1137, p 1137 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	mesenchymal stem cells stroke motor recovery post hoc analysis motor impairment Medicine R
spellingShingle	mesenchymal stem cells stroke motor recovery post hoc analysis motor impairment Medicine R Won Hyuk Chang Jungsoo Lee Jong-Won Chung Yun-Hee Kim Oh Young Bang The STARTING-2 Collaborators Probable Factors Associated with Response to Mesenchymal Stem Cell Therapy in Stroke Patients: A Post Hoc Analysis of the STARTING-2 Trial
description	The aim of this study was to identify factors associated with improved motor function of the lower extremities in response to mesenchymal stem cell (MSC) therapy in patients with ischemic stroke. This study was a post hoc analysis of data from a prospective, open-label, randomized controlled trial of MSC therapy for patients with ischemic stroke patients associated with severe middle cerebral artery territory (STARTING-2 trial). Lower limb motor function was scored based on the lower limb of Fugl–Meyer assessment (FMA-LL) score before MSC therapy and at 3 months after stroke. All FMA-LL changes greater than or equal to six points were considered clinically significant. Univariate and multivariate binary logistic regression models were used to determine possible predictors of clinically significant lower limb motor response to MSC therapy. Twelve (33%) of the thirty-six patients receiving MSC therapy reached a minimal clinically important difference (MCID) of FMA-LL. The two independent factors with the greatest impact on response to MSC therapy for achieving an MCID in FMA-LL score were: (1) the time from stroke onset to MSC therapy, and (2) age (<i>p</i> < 0.05). In addition, obese stroke patients responded better to MSC therapy than stroke patients with normal weight. In conclusion, this post hoc analysis might suggest the need for recruiting stroke patients at younger and early after stroke onset in future clinical trials of MSC therapy for stroke.
format	article
author	Won Hyuk Chang Jungsoo Lee Jong-Won Chung Yun-Hee Kim Oh Young Bang The STARTING-2 Collaborators
author_facet	Won Hyuk Chang Jungsoo Lee Jong-Won Chung Yun-Hee Kim Oh Young Bang The STARTING-2 Collaborators
author_sort	Won Hyuk Chang
title	Probable Factors Associated with Response to Mesenchymal Stem Cell Therapy in Stroke Patients: A Post Hoc Analysis of the STARTING-2 Trial
title_short	Probable Factors Associated with Response to Mesenchymal Stem Cell Therapy in Stroke Patients: A Post Hoc Analysis of the STARTING-2 Trial
title_full	Probable Factors Associated with Response to Mesenchymal Stem Cell Therapy in Stroke Patients: A Post Hoc Analysis of the STARTING-2 Trial
title_fullStr	Probable Factors Associated with Response to Mesenchymal Stem Cell Therapy in Stroke Patients: A Post Hoc Analysis of the STARTING-2 Trial
title_full_unstemmed	Probable Factors Associated with Response to Mesenchymal Stem Cell Therapy in Stroke Patients: A Post Hoc Analysis of the STARTING-2 Trial
title_sort	probable factors associated with response to mesenchymal stem cell therapy in stroke patients: a post hoc analysis of the starting-2 trial
publisher	MDPI AG
publishDate	2021
url	https://doaj.org/article/a80a79b6f65f4a5f9024672142dad666
work_keys_str_mv	AT wonhyukchang probablefactorsassociatedwithresponsetomesenchymalstemcelltherapyinstrokepatientsaposthocanalysisofthestarting2trial AT jungsoolee probablefactorsassociatedwithresponsetomesenchymalstemcelltherapyinstrokepatientsaposthocanalysisofthestarting2trial AT jongwonchung probablefactorsassociatedwithresponsetomesenchymalstemcelltherapyinstrokepatientsaposthocanalysisofthestarting2trial AT yunheekim probablefactorsassociatedwithresponsetomesenchymalstemcelltherapyinstrokepatientsaposthocanalysisofthestarting2trial AT ohyoungbang probablefactorsassociatedwithresponsetomesenchymalstemcelltherapyinstrokepatientsaposthocanalysisofthestarting2trial AT thestarting2collaborators probablefactorsassociatedwithresponsetomesenchymalstemcelltherapyinstrokepatientsaposthocanalysisofthestarting2trial
_version_	1718411634351800320

Probable Factors Associated with Response to Mesenchymal Stem Cell Therapy in Stroke Patients: A Post Hoc Analysis of the STARTING-2 Trial

Ejemplares similares